#### FONTES et al. U.S. National Phase of PCT/FR2003/002236

### **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-22 canceled

- 23. (new) A method for the treatment of peripheral neuropathies, comprising administering to a subject affected by or presenting a risk of developing such pathology, an effective amount of cAMP modulator.
- 24. (new) The method according to claim 23, for the treatment of demyelinating peripheral neuropathies.
- 25. (new) The method according to claim 23, wherein the cAMP modulator is an inhibitor of said cAMP.
- 26. (new) The method according to claim 23, wherein the cAMP modulator is vitamin C or a derivative thereof.
- 27. (new) The method according to claim 23, for the treatment of hereditary peripheral neuropathies.
- 28. (new) The method according to claim 23, for the treatment of Charcot-Marie-Tooth disease.

# FONTES et al. U.S. National Phase of PCT/FR2003/002236

- 29. (new) The method according to claim 23, for the treatment of type I Charcot-MarieTooth disease (CMTI).
- 30. (new) The method according to claim 23, for the treatment of non-hereditary peripheral neuropathies.
- 31. (new) The method according to claim 23, wherein cAMP modulator is selected in the group consisting of natural vitamin C, synthetic vitamin C and a mixture thereof.
- 32. (new) The method according to claim 23, wherein cAMP modulator is selected in the group consisting of vitamin C salts and esters.
- 33. (new) The method according to claim 23, wherein cAMP modulator is a vitamin C derivative selected in the group consisting of ascorbyl palmitate, dipalmitate L-ascorbate and their mixture or in the group consisting of glycosylated, mannosylated, fructosylated, fucosylated, galactosylated, Nacetylglucosaminated, N-acetylmuramic derivatives of ascorbic acid and their mixtures, preferably ascorbyl-2 glucoside, 2-O-alpha-D-glucopyranosyl ascorbic acid or 6-O-beta-D-galactopyranosyl L-ascorbic acid.
- 34. (new) The method according to claim 23, wherein cAMP modulator is a vitamin

## FONTES et al. U.S. National Phase of PCT/FR2003/002236

C derivative selected in the group consisting of the metal salts of phosphorylated ascorbic acid, in particular the alkaline metal ascorbyl phosphates, the alkaline earth metal ascorbyl phosphates and the transition metal ascorbyl phosphates, preferably magnesium ascorbyl phosphate or else the ascorbyl sulfates.

- 35. (new) The method according to claim 23, for regulating cAMP expression.
- 36. (new) The method according to claim 23, for reducing cAMP expression.
- 37. (new) The method according to claim 23, for regulating the expression of the PMP22 protein.
- 38. (new) The method according to claim 23, for reducing the expression of the PMP22 protein.
- 39. (new) Method for preparing a composition for treating peripheral neuropathies wherein the composition comprises as active substance a cAMP modulator that can be assimilated by humans or animals, in association with a pharmaceutically acceptable vehicle.
- 40. (new) Method according to claim 39, wherein the cAMP modulator is an inhibitor of said cAMP.

### FONTES et al. U.S. National Phase of PCT/FR2003/002236

- 41. (new) Method according to claim 39, wherein the cAMP modulator is ascorbic acid or a derivative thereof that can be assimilated by humans or animals.
- 42. (new) Method according to claim 39, wherein the cAMP modulator is the vitamin C selected in the group consisting of natural vitamin C, synthetic vitamin C and a mixture thereof.
- 43. (new) Method according to claim 39, wherein the composition comprises 250 milligrams to 6 grams of vitamin C or a vitamin C derivative.
- 44. (new) Kit intended for implementing a method according to claim 39.